ALNY logo

Alnylam Pharmaceuticals

ALNY · What the business does, what can go wrong, and how options sellers approach it

What it does

Alnylam is a biotechnology company built around RNA interference (RNAi). This is a natural process in cells that switches off specific genes. Alnylam designs medicines that use this process to reduce the production of disease-causing proteins, often at the source.

Its approved products treat conditions such as hATTR amyloidosis, acute hepatic porphyria and primary hyperoxaluria type 1. It also has a pipeline in areas like cardio-metabolic disease, neuroscience and hematology.

How it makes money

Alnylam sells its own approved medicines, mainly to patients with rare or under-served diseases. These drugs are typically specialty therapies with high prices per patient and smaller patient populations.

It also earns revenue from partners. Some RNAi-based drugs, such as those for high cholesterol and hemophilia, are commercialized by larger pharmaceutical companies, and Alnylam can receive royalties and milestone payments from them.

Why investors own it

Investors often view Alnylam as a platform company in RNAi. One technology can be applied to many targets, so success in one area may carry over into others.

Some also like that it has moved from a research-stage company to one with several marketed products, and that its pipeline offers potential for new uses.

What can go wrong

  • Clinical trials can fail or be delayed, and regulators may decline or restrict approvals.
  • Competing treatments, including other RNA-based drugs and different drug types, could take market share.
  • Pricing pressure from insurers, governments and policy changes could limit revenue.
  • Heavy research spending can weigh on profits, and the company may need to raise capital.
  • Revenue depends heavily on a small number of products.

What to watch

  • Product sales growth for its main medicines
  • Number of patients starting and staying on therapy
  • Clinical trial readouts and regulatory decisions
  • Partner royalties and milestone payments
  • Operating expenses and progress toward sustained profitability
  • Competitive drug approvals in its key disease areas

Options income angle

Options on ALNY are generally liquid, though trading depth can vary by strike and expiration. Implied volatility tends to rise ahead of earnings, trial results and regulatory decisions, and it can fall sharply once the news is out.

One caution for premium sellers: biotech stocks can gap sharply on trial or regulatory news. A short call can cap gains in a big rally, and a short put can lead to large losses if the stock drops quickly. Selling premium through event dates carries extra risk.

Follow ALNY in Kortex

The Kortex app shows ALNY's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.